Temocillin in cystic fibrosis: a retrospective pilot study

Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
Lisa KentJ Stuart Elborn

Abstract

Temocillin is currently used in the treatment of acute pulmonary exacerbations caused by Burkholderia cepacia complex and multi-resistant Pseudomonas aeruginosa in cystic fibrosis (CF) patients despite little published clinical data. This study assessed if intravenous (IV) antibiotic therapy including temocillin was equivalent to standard combination therapy for an acute exacerbation. A retrospective, pilot cross-over study. Adult patients attending two CF centres between 1997 and 2006 who had received a course of IV antibiotics including temocillin (TIV) and a further IV course (within +/-1 year) which did not include temocillin (NTIV) were included. Outcome measures at the start and end of each IV course were recorded (FEV(1)%, FVC%). Twenty six patients had received temocillin. Baseline values of FEV(1)% predicted were comparable for both groups (TIV: 37(18%), NTIV: 39(20%)). FEV(1)% increased by 7.12(11.67)% after TIV (p<0.01) and 6.65(7.62)% after NTIV (p<0.01). There was no significant difference between the IV courses in mean %change in lung function TIV versus NTIV (FEV(1) 0.46% [95%CI: -4.55 to 5.48%]). These data suggest equivalence in the lung function outcome of IV antibiotic therapy includingtemocillin versus stand...Continue Reading

References

Jan 1, 1985·Drugs·J D Williams, H Y Chen
Jan 1, 1985·Drugs·A CockburnD J White
Jan 1, 1985·Drugs·J M GrayJ D Sleigh
Jan 1, 1984·Antimicrobial Agents and Chemotherapy·L Verbist, J Verhaegen
Apr 1, 1982·Antimicrobial Agents and Chemotherapy·R BolivarG P Bodey
Jul 1, 1982·Antimicrobial Agents and Chemotherapy·L Verbist
Sep 1, 1982·Antimicrobial Agents and Chemotherapy·K Jules, H C Neu
Feb 28, 2006·The Journal of Antimicrobial Chemotherapy·Hector Rodriguez-VillalobosMarc J Struelens
May 3, 2006·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Anastasios LekkasMargaret E Hodson

❮ Previous
Next ❯

Citations

Jun 17, 2011·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Robert BalsBurkhard Tümmler
Jul 8, 2010·The Journal of Antimicrobial Chemotherapy·M D Parkins, J S Elborn
Sep 21, 2010·Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society·Heleen Van AckerTom Coenye
Mar 17, 2015·Expert Review of Anti-infective Therapy·Vikas GautamAmit Agarwal

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

CFTR Mutant Structural Therapy

Over 1700 different mutations in the CFTR genes have been shown to cause cystic fibrosis. Here is the latest research on structural therapy for CFTR mutants.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Related Papers

Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
Anastasios LekkasMargaret E Hodson
The Journal of Antimicrobial Chemotherapy
David M Livermore, Paul M Tulkens
© 2022 Meta ULC. All rights reserved